2-(dimethylamino)-2-oxoethyl acetate | 13831-28-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-(dimethylamino)-2-oxoethyl acetate
• 英文别名: N,N-Dimethyl-O-acetyl-glykolsaeureamid；2-(Acetyloxy)-N,N-dimethylacetamide；[2-(dimethylamino)-2-oxoethyl] acetate
• CAS: 13831-28-2
• 化学式: C₆H₁₁NO₃
• 分子量: 145.158
• InChiKey: CWYWDHYMHWDYPR-UHFFFAOYSA-N

物化性质

• 熔点：
  54 °C
• 沸点：
  215.5±23.0 °C(Predicted)
• 密度：
  1.071±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(dimethylamino)-2-oxoethyl acetate 在 potassium carbonate 作用下， 以 氯仿 为溶剂， 生成 Acetic acid bis-dimethylcarbamoyl-methyl ester
  参考文献：
  名称：

  Phosgene immonium salts. XIII. Dichloromalonyl cyanines and 3,5-bis(dimethylamino)pyrazoles

  摘要：

  DOI：

  10.1021/jo00923a015
• 作为产物：
  描述：

  lead(IV) tetraacetate 、 Triethylstannylessigsaeure-dimethylamid 在 乙酸三甲基锡 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 以85%的产率得到2-(dimethylamino)-2-oxoethyl acetate
  参考文献：
  名称：

  Reactions of stannylacetic acid derivatives with lead tetraacetate

  摘要：

  DOI：

  10.1007/bf00954394

文献信息

• Cu(<scp>ii</scp>)-Mediated keto C(sp³)–H bond α-acyloxylation of N,N-dialkylamides with aromatic carboxylic acids
  作者：Wenjing Li、Changzhen Yin、Xiao Yang、Hailong Liu、Xueli Zheng、Maolin Yuan、Ruixiang Li、Haiyan Fu、Hua Chen

  DOI：10.1039/c7ob01190c

  日期：——

  The first example of Cu(ii)-mediated oxidative coupling of aromatic carboxylic acids with the C(sp³)–H bond adjacent to the keto group ofN,N-dialkylamides has been developed.

  铜(II)催化的芳香羧酸与N,N-二烷基酰胺的酮基邻位C(sp³)–H键的氧化偶联的第一个例子已经被开发出来。

• [EN] ARYLOXYACETYLINDOLES AND ANALOGS AS ANTIBIOTIC TOLERANCE INHIBITORS<br/>[FR] ARYLOXYACÉTYLINDOLES ET ANALOGUES EN TANT QU'INHIBITEURS DE TOLÉRANCE AUX ANTIBIOTIQUES
  申请人：SPERO THERAPEUTICS INC

  公开号：WO2016112088A1

  公开（公告）日：2016-07-14

  The disclosure provides compounds and pharmaceutical compositions of aryloxyacetylindoles compounds and analogs useful for treating chronic and acute bacterial infections. Certain of the compounds are compounds of general Formula (I) (I) or a pharmaceutically acceptable salt or prodrug thereof. Certain compounds of this disclosure are MvfR inhibitors. MvfR inhibitors reduce the formation of antibiotic tolerant bacterial strains and are useful for treating Gram-negative bacterial infections and reducing the virulence of Pseudomonas aeruginosa. Methods of treating bacterial infections in a subject, including Pseudomonas aeruginosa infections, are also provided by the disclosure.

  该披露提供了芳基氧乙酰基吲哚化合物及类似物的化合物和药物组合物，用于治疗慢性和急性细菌感染。其中某些化合物是一般式(I)（I）的化合物或其药用可接受的盐或前药。该披露的某些化合物是MvfR抑制剂。MvfR抑制剂减少抗生素耐药细菌菌株的形成，对治疗革兰氏阴性细菌感染和减少铜绿假单胞菌的毒力有用。该披露还提供了治疗受试者细菌感染的方法，包括铜绿假单胞菌感染。
• [EN] ALKYNE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS<br/>[FR] COMPOSÉS DE TYPE ALCYNE EN TANT QU'INHIBITEURS DE LA S-NITROSOGLUTATHIONE RÉDUCTASE
  申请人：GLENMARK PHARMACEUTICALS SA

  公开号：WO2016055947A1

  公开（公告）日：2016-04-14

  Provided are compounds of formula (Ia) and pharmaceutically acceptable salts thereof, wherein A, B, R 1, R 2, m and n are as defined herein, which are active as inhibitors of S-Nitrosoglutathione reductase (GSNOR). These compounds prevent, inhibit, or suppress the action of GSNOR and are therefore useful in the treatment of GSNOR mediated diseases, disorders, syndromes or conditions such as, e.g., pulmonary hypertension, acute respiratory distress syndrome (ARDS), asthma, bronchospasm, cough, pneumonia, pulmonary fibrosis, interstitial lung diseases, cystic fibrosis and chronic obstructive pulmonary disease (COPD).

  提供的是式(Ia)的化合物及其药学上可接受的盐，其中A、B、R1、R2、m和n如本文所定义，这些化合物作为S-硝基谷胱甘肽还原酶(GSNOR)的抑制剂具有活性。这些化合物可以预防、抑制或抑制GSNOR的作用，因此在治疗GSNOR介导的疾病、疾病、综合征或病症方面具有用处，例如肺动脉高压、急性呼吸窘迫综合征(ARDS)、哮喘、支气管痉挛、咳嗽、肺炎、肺纤维化、间质性肺疾病、囊性纤维化和慢性阻塞性肺疾病(COPD)。
• Prodrug derivatives of carboxylic acid drugs
  申请人：——

  公开号：US05073641A1

  公开（公告）日：1991-12-17

  ##STR1## Novel ester derivatives of carboxylic acid medicaments of formula (I), wherein R--COO--represents the acyloxy residue of a carboxylic acid drug or medicament, n is an integrer from 1 to 3, and R.sub.1 and R.sub.2 are the same or different and are selected from a group consisting of an alkyl, an alkenyl, an aryl, an aralkyl, a cycloalkyl and which group may be unsubstituted or substituted, or R.sub.1 and R.sub.2 together with the N forms a 4-, 5-, 6- or 7-membered heterocyclic ring, which in addition to the nitrogen atom may contain one or two further heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and which heterocyclic group may be substituted. These compounds are highly biolabile prodrug forms of the corresponding carboxylic acid compounds and are highly susceptible to undergoing enzymatic hydrolysis in vivo whereas they are highly stable in aqueous solution. The novel derivatives are less irritating to mucosa than the parent carboxylic acids and may provide an improved bio-availability of the drugs.

  化合物的式子为(I)，其中R-COO-代表羧酸药物或药剂的乙酰氧基残基，n为1到3的整数，R1和R2相同或不同，选择自烷基，烯基，芳基，芳基烷基，环烷基的一组，该组可能未被取代或被取代，或R1和R2与N一起形成4，5，6或7成员杂环环，除氮原子外还可能含有来自氮，氧和硫的另外一或两个杂原子，且该杂环基可能被取代。这些化合物是相应的羧酸化合物的高度生物可利用的前药形式，极易在体内经历酶促水解，而在水溶液中则高度稳定。这些新的衍生物比原始的羧酸对黏膜的刺激性更小，并且可能提供更好的生物利用度。
• ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES
  申请人：Marfat Anthony

  公开号：US20070161681A1

  公开（公告）日：2007-07-12

  Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructive pulmonary disease, of the formula: wherein the substituents are as defined in the specification.

  以下化合物可用作PDE4的抑制剂，用于治疗由嗜酸性粒细胞的活化和脱颗粒调控的疾病，特别是哮喘、慢性支气管炎和慢性阻塞性肺疾病，其化学式如下：其中取代基如规范中所定义。